What Is Drawing Fresh Attention To BridgeBio Pharma (BBIO)?
BridgeBio Pharma (BBIO) is gaining investor attention due to recent positive clinical trial data for BBP-418 and acoramidis, despite a recent dip in share price. While one valuation narrative suggests the company is 169% overvalued, another DCF model indicates it trades significantly below fair value. This discrepancy highlights differing views on the company's future commercial success and clinical/regulatory risks.
About 1 in 25 Black Americans carries a gene variant linked to heart disease. Education events will span 40 locations.
BridgeBio Pharma is launching a nationwide education effort with community partners to raise awareness about transthyretin amyloid cardiomyopathy (ATTR-CM), an underrecognized cause of heart failure, particularly affecting Black Americans. The initiative, starting with a YouTube premiere on October 6th and continuing through World Amyloidosis Day on October 26th, will involve educational programming at 40 locations. This effort aims to bridge the gap in understanding ATTR-CM, especially given that approximately 1 in 25 Black Americans carries a genetic variant associated with the condition.
Jefferies reiterates Buy on BridgeBio Pharma stock, $110 target By Investing.com
Jefferies has reiterated a Buy rating on BridgeBio Pharma (NASDAQ:BBIO) with a $110 price target, citing new Phase III analyses for BBP-418 that support its disease-modifying potential in LGMD2I/R9, a rare muscle disease. The firm maintains high conviction in the drug's full approval by November 27, 2026, and believes its peak sales estimate of over $1 billion is conservative, given the company's strong gross profit margin and revenue growth. Other analysts from H.C. Wainwright, Mizuho, TD Cowen, and Cantor Fitzgerald have also provided positive updates, reflecting ongoing interest and favorable outlook for BridgeBio Pharma's drug pipeline.
BridgeBio Pharma stock presents new cardiac data for BBP-418 trial
BridgeBio Pharma (BBIO) presented new 12-month cardiac data from its Phase 3 FORTIFY trial for BBP-418, an investigational oral therapy for LGMD2I/R9. The data showed significant improvement in cardiac markers, with 100% of treated participants achieving normal troponin I levels, compared to 40% in the placebo group. The company's Q2 2026 revenue of $243.7 million exceeded consensus estimates, and BBP-418 is currently under FDA Priority Review with a target action date of November 27, 2026.
BridgeBio Pharma Reports Positive Cardiac Data from Phase 3 FORTIFY Trial of BBP-418 in LGMD2I/R9
BridgeBio Pharma announced positive cardiac data from the Phase 3 FORTIFY trial of BBP-418 for LGMD2I/R9. Exploratory analyses showed that BBP-418 normalized high-sensitivity troponin I levels in 100% of treated patients with elevated baseline levels, compared to 40% in the placebo group, and improved left ventricular ejection fraction in 54% of patients. The drug is currently under FDA Priority Review with a target decision date of November 27, 2026, indicating its potential as a disease-modifying therapy.
Heart-injury markers normalized in all treated people who started high; 40% on placebo.
BridgeBio Pharma presented positive exploratory cardiac results from the interim analysis of its Phase 3 FORTIFY trial for BBP-418, a potential disease-modifying therapy for limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). The data showed that 100% of participants treated with BBP-418 with elevated baseline high-sensitivity troponin I normalized by Month 12, compared to 40% on placebo. BBP-418 is currently under FDA Priority Review with a target action date of November 27, 2026, and the company plans further studies in pediatric and other LGMD populations.
BridgeBio Pharma Investors Are Up 27%. What Case Did They Back?
BridgeBio Pharma investors have seen a 27.2% return over the past year, driven by events like the Attruby launch and new trial data. The article discusses two opposing views investors faced a year ago: a bullish outlook anticipating high revenue growth and profit margins, and a bearish one concerned about reliance on Attruby and high operating costs. While recent Q2 2026 revenue of US$243.676 million showed improved net margin, profit remains negative, suggesting the optimistic commercial execution is backed but profitability is not yet proven.
BridgeBio Pharma, Inc. (BBIO) Stock Price, News, Quote & History
BridgeBio Pharma, Inc. (BBIO) is a biopharmaceutical company focused on developing medicines for genetic diseases. The article provides current stock performance data, including its price, recent changes, and historical returns, alongside key financial metrics and an overview of its product pipeline, such as Attruby and Encaleret. Analyst ratings and target prices are also included, indicating a positive outlook for the company.
The Speak Foundation Announces $300,000 BridgeBio Commitment to Advance Patient-Led LGMD Centers of Excellence
The Speak Foundation has announced a $300,000 commitment over two years from BridgeBio Pharma, Inc. to expand its patient-led LGMD Centers of Excellence program. This initiative aims to improve specialized care, research readiness, and access to emerging treatments for people living with limb-girdle muscular dystrophy. The program focuses on replacing fragmented care with coordinated, expert care tailored to patient needs.
(BBIO) Movement as an Input in Quant Signal Sets
Bridgebio Pharma Inc. (NASDAQ: BBIO) is showing weak near and mid-term sentiment, potentially challenging its long-term positive outlook, with no clear price positioning signal and elevated downside risk. AI models have generated three trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—each tailored to different risk profiles and incorporating sophisticated risk management. Long-term analysis for BBIO, however, shows strong signals with support at $77.32 and resistance at $87.72.
Debt to assets ratio of BridgeBio Pharma, Inc. – HAN:2CL
This article provides financial information for BridgeBio Pharma, Inc. (HAN:2CL) on the Hannover Stock Exchange, specifically focusing on its debt to assets ratio. It indicates that the market is closed and no trades have occurred for this particular stock.
BridgeBio Pharma, Inc. Revenue Breakdown – HAN:2CL
BridgeBio Pharma, Inc. (HAN:2CL) generated €427.48 million in revenue last year, with its Transformative Medicines segment being the top performer at €308.53 million. The United States was the primary regional contributor, accounting for €308.64 million of the revenue. This data provides a breakdown of the company's financial performance by segment and geographical source.
BridgeBio Pharma (BBIO) Following Acoramidis Study Faces A Wide Fair Value Debate
BridgeBio Pharma (BBIO) is facing a significant debate over its fair value after publishing a study on acoramidis, its ATTR cardiomyopathy treatment. Despite a recent stock price dip, the company's long-term returns remain strong. The article highlights two contrasting valuations: one analyst narrative suggests BBIO is 162.3% overvalued at $25, citing challenges from Pfizer and Alnylam, while Simply Wall St's DCF model estimates a fair value of $281.61.
BBIO5151039 Bond Profile: Coupon and Redemption
This article provides a detailed profile of the BridgeBio Pharma, Inc. (BBIO5151039) 2.5% bond maturing on March 15, 2027. It outlines key facts such as the issuer, maturity date, face value, and highlights the semi-annual fixed-rate coupon payments, including a schedule of past and upcoming payouts. The bond's outstanding amount is 550.00M USD, with redemption type made by humans.
BridgeBio Pharma Eyes Four Global Launches by 2027 as Attruby Nears Blockbuster Status
BridgeBio Pharma (NASDAQ: BBIO) anticipates a transformative year in 2027, expecting to expand from one commercial product to four globally launched therapies, as stated by President and CFO Thomas Trimarchi. The company's lead product, Attruby, an ATTR cardiomyopathy treatment, is annualizing over $1 billion globally and is projected to reach blockbuster status by year-end, with peak sales potentially exceeding $4 billion. BridgeBio also has several rare disease therapies, including BBP-418 for limb-girdle muscular dystrophy and encaleret for ADH1, nearing regulatory decisions, and infigratinib for achondroplasia in its pipeline.
BridgeBio Pharma Eyes Four Global Launches by 2027 as Attruby Nears Blockbuster Status
BridgeBio Pharma anticipates a transformative year in 2027, projecting an expansion from one to four globally launched therapies, as stated by President and CFO Thomas Trimarchi. Their current drug, Attruby, for ATTR cardiomyopathy, is already annualizing over $1 billion globally and is expected to reach blockbuster status by year-end. The company is also progressing with three other rare disease therapies, BBP-418, encaleret, and infigratinib, with significant milestones expected in the near future.
BridgeBio Pharma (BBIO) Reports 34% Lower Risk Of Early Clinical Worsening
BridgeBio Pharma (BBIO) announced that its drug acoramidis showed a 34% lower risk of early clinical worsening and better results for early heart failure progression markers compared to tafamidis in a new peer-reviewed real-world study for ATTR-CM. The study also noted a 43% lower risk of diuretic intensification with acoramidis. This data supports the narrative of acoramidis as a key growth driver for BridgeBio Pharma, reinforcing its differentiation in the treatment of ATTR-CM.
TD Cowen Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $110
TD Cowen has reiterated its Buy rating for BridgeBio Pharma (BBIO.US) and maintained its target price at $110. This indicates the firm's continued positive outlook on the company's stock performance.
BridgeBio says heart disease therapy Attruby beat Pfizer’s Vyndamax in real world study
BridgeBio Pharma announced that its heart disease therapy, acoramidis (Attruby), demonstrated superior performance compared to Pfizer's tafamidis (Vyndamax) in a real-world study. Attruby received FDA approval in November 2024 for transthyretin cardiac amyloidosis. This news highlights a potential competitive advantage for BridgeBio in the cardiovascular treatment market.
BridgeBio Pharma Announces Real-World Study Showing Acoramidis Reduced Clinical Worsening Versus Tafamidis in ATTR-CM
BridgeBio Pharma announced a real-world study showing that its drug acoramidis significantly reduced clinical worsening events by 34% and diuretic intensification risk by 43% compared to tafamidis in patients with transthyretin amyloid cardiomyopathy (ATTR-CM). These benefits appeared quickly and strengthened over time, suggesting acoramidis has a distinct clinical advantage for ATTR-CM treatment. The findings, published in Cardiology and Therapy, indicate that acoramidis could become a preferred treatment option, with further independent study results expected in 2026.
BridgeBio Pharma (BBIO) Stock Looks Properly Priced For Its Sales Story
BridgeBio Pharma's stock has surged 160.5% over the past three years, leading to its current valuation of US$69.23. The company trades at a P/S ratio of 19.0x, which is higher than the biotech industry average, indicating that its current price already reflects significant confidence in future sales growth. While some analysts see the stock as undervalued due to its rapid pipeline progress and AI/genomics leverage, others believe it is overvalued, citing increased competition in its therapeutic areas.
BridgeBio Pharma stock finds support near USD 66
BridgeBio Pharma (BBIO) stock traded at USD 66.85 on September 22, 2026, near a potential support level of USD 66, although this support is not yet confirmed. The company reported USD 502.08 million in revenue but a net loss of USD 724.93 million in fiscal 2025, alongside significant long-term debt. Analysts, however, have a much higher average 12-month price target of USD 108.92 for the stock.
BridgeBio Pharma CEO Neil Kumar sells $690,847 in shares
BridgeBio Pharma CEO Neil Kumar sold 10,000 shares of the company's common stock for over $690,000 on September 17, 2026, under a Rule 10b5-1 plan. The sale was executed through a family trust, and his remaining beneficial ownership includes millions of shares across various trusts and directly. This transaction occurred as BBIO stock experienced a recent downturn but remains up over the past year, with InvestingPro analysis suggesting it is slightly overvalued.
BridgeBio (NASDAQ: BBIO) CEO’s trust sells 10,000 shares under preset plan
BridgeBio Pharma's CEO, Neil Kumar, had trusts associated with him sell 10,000 shares of common stock on September 17, 2026, under a Rule 10b5-1 sales plan. The sales, executed by the Kumar Haldea Family Irrevocable Trust, occurred in two transactions with weighted average prices ranging from $68.52 to $69.64 per share. Despite these sales, Kumar retains significant indirect and direct holdings in the company.
7 Red Days In A Row: BridgeBio Pharma Stock Is Down 12%
BridgeBio Pharma (BBIO) stock has experienced a significant 12.4% drop over seven consecutive trading days, resulting in a $1.9 billion reduction in its market value. Despite rapid revenue growth of 202.4% over the last twelve months, the company faces substantial operating losses with a margin of -67.0%. The article emphasizes that while such a streak highlights downward momentum, investors should focus on fundamentals rather than reacting solely to price movements.
BridgeBio Pharma at Morgan Stanley conference: attruby drives growth
BridgeBio Pharma presented at the Morgan Stanley 24th Annual Global Healthcare Conference, highlighting the growth of its commercial franchise, particularly Attruby sales, and a robust late-stage pipeline. The company is targeting operational break-even by late 2027 to early 2028 and cash flow generation in 2028, driven by new drug launches and market expansion. Management discussed the clinical differentiation of Attruby, the potential of upcoming treatments for achondroplasia, limb-girdle muscular dystrophy, and ADH1, and addressed market dynamics, pricing strategies, and the impact of AI and China on its business.
133,900 Preferred Stock of BridgeBio Pharma, Inc. are subject to a Lock-Up Agreement Ending on 13-SEP-2026.
133,900 Preferred Stock of BridgeBio Pharma, Inc. are subject to a lock-up agreement that ends on September 13, 2026. This lock-up period began on August 13, 2026, and lasts for 31 days. The agreement prevents the selling stockholder from disposing of or hedging common stock or convertible securities during this period without underwriter consent, but does not apply to employee benefit plans.
H.C. Wainwright reiterates BridgeBio Pharma stock rating at buy By Investing.com
H.C. Wainwright has reiterated its Buy rating for BridgeBio Pharma (NASDAQ:BBIO) with a $120.00 price target. This decision follows promising exploratory analyses from the PROPEL 3 study for achondroplasia and strong Q2 2026 revenue, which surpassed analyst estimates due to robust Attruby sales. Other firms like Piper Sandler, Canaccord, and Mizuho have also raised their price targets for BridgeBio Pharma.
BridgeBio Pharma (BBIO) Down 10.7% Since Last Earnings Report: Can It Rebound?
BridgeBio Pharma (BBIO) shares have dropped 10.7% since its last earnings report, underperforming the S&P 500. The company reported a wider-than-expected Q2 2026 loss per share but revenues surged, primarily driven by strong sales of Attruby. Analyst estimates have shown a downward trend for the stock, which currently holds a Zacks Rank #3 (Hold).
9 Red Days In A Row: BridgeBio Pharma Stock Is Down 8.8%
BridgeBio Pharma (BBIO) stock has experienced an 8.8% decline over nine consecutive trading days, resulting in a $1.4 billion market value loss. Despite this recent slide, the stock has shown significant returns over the trailing three and twelve months, and its revenue growth is substantial. The article highlights that the decline is specific to the company and suggests re-evaluating the business fundamentals rather than reacting solely to the momentum.
BridgeBio to Participate in September Investor Conferences
BridgeBio Pharma, Inc. announced its participation in four healthcare investor conferences in September 2026, including the Wells Fargo, Cantor Global, Morgan Stanley Global, and Bernstein Insights conferences. Management will present at these events, and live webcasts and replays will be available on the company's investor relations website. BridgeBio focuses on developing transformative medicines for genetic conditions using a decentralized model.
Trump Announces Drug Pricing Deals With Teva and 8 Other Companies
President Donald Trump announced new drug pricing deals with the U.S. affiliate of Teva Pharmaceutical Industries and eight other midsize companies. This builds on previous agreements, bringing the total number of major pharmaceutical companies with pricing agreements with the Trump administration to 17. The announcement was made during an event in the Oval Office.
7 Red Days In A Row: BridgeBio Pharma Stock Is Down 8.8%
BridgeBio Pharma (BBIO) stock has experienced a seven-day decline, dropping 8.8% and erasing approximately $1.4 billion from its market value. This movement is specific to BBIO, as the S&P 500 remained flat during the same period. While the company boasts substantial revenue growth (202.4% over the last twelve months), it faces significant profitability challenges with a -67.0% operating margin.
Trump Strikes Medicaid Drug Price Deals With Nine Pharma Firms
The Trump administration has finalized drug pricing agreements with nine biotech and pharmaceutical companies, aiming to secure the "lowest prices available anywhere in the world" for outpatient drugs for state Medicaid programs. This initiative is part of an ongoing effort to address healthcare affordability, with the president claiming 26 companies representing 90% of the domestic pharmaceutical market have now signed on to most-favored nation discounts. Researchers estimate that this Medicaid drug pricing pilot could save states over $8 billion annually if widely applied to high-cost brand-name drugs.
Bridgebio Pharma Presents New Analyses from Phase 3 Attribute-Cm Study of Attruby in Transthyretin Amyloid Cardiomyopathy
BridgeBio Pharma presented new analyses from its Phase 3 ATTRibute-CM study of Attruby (acoramidis) for transthyretin amyloid cardiomyopathy (ATTR-CM) at the European Society of Cardiology Congress 2026. The analyses, including a cardiac magnetic resonance imaging (CMR) substudy and open-label extension, suggest that acoramidis can reverse disease progression, significantly reduce days lost to death and/or cardiovascular-related hospitalization (DLDCVH), and improve health-related quality of life and heart failure-related health status. The drug remained well-tolerated with long-term durability of efficacy and safety, particularly in variant ATTR-CM patients, including the high-risk p.Val142Ile subgroup.
BridgeBio Pharma Doses First Patient in Trial Evaluating Long-Term Impact of Heart Disease Medicine
BridgeBio Pharma has dosed the first patient in a clinical trial designed to evaluate the long-term impact of its heart disease medicine. The article notes recent insider share sales and updates on analyst ratings and the company's financial performance, including Q2 2026 earnings. BridgeBio Pharma is focused on developing transformative medicines for genetic diseases, with a pipeline that includes treatments for conditions like ATTR-CM and achondroplasia.
BridgeBio doses first patient in acoramidis heart study By Investing.com
BridgeBio Pharma Inc. announced the dosing of the first patient in its ASCEND-ATTR study, a Phase 3b/4 clinical trial investigating the long-term effects of acoramidis on cardiac structure, function, and amyloid burden in patients with transthyretin amyloid cardiomyopathy (ATTR-CM). The study will enroll approximately 150 participants and evaluate outcomes over 36 months, building on previous findings that showed acoramidis was associated with improvements in cardiac measurements. Acoramidis, marketed as Attruby, is already indicated for treating the cardiomyopathy of ATTR amyloidosis to reduce cardiovascular death and hospitalizations.
BridgeBio will study about 150 patients for 3 years to see if hearts improve
BridgeBio Pharma has dosed the first participant in its ASCEND-ATTR study, a Phase 3b/4 trial evaluating the long-term effects of acoramidis (Attruby) on cardiac structure, function, and amyloid burden in approximately 150 adults with transthyretin amyloid cardiomyopathy (ATTR-CM). The 36-month study aims to determine if acoramidis can not only slow disease progression but also actively restore heart health, building on prior data suggesting cardiac improvement and amyloid regression. Attruby is already approved for reducing cardiovascular death and hospitalizations in ATTR-CM patients.
Is BBIO a Buy as Fast Sales Growth Meets a Steep Valuation Premium?
BridgeBio Pharma (BBIO) is at a critical juncture, balancing rapid sales growth from its drug Attruby and the potential for new product launches, against a demanding valuation and ongoing losses. While Attruby's sales are surging and three late-stage candidates could broaden revenue streams, the company faces significant execution and concentration risks. Its current Zacks Rank #3 (Hold) reflects a measured outlook, emphasizing that future performance hinges on successful product launches and market penetration to justify its high valuation premium.
BridgeBio Skids Ahead of Munich Conference
BridgeBio Pharma (NASDAQ: BBIO) shares declined ahead of the European Society of Cardiology (ESC) Congress 2026, where the company will present new data on its drug acoramidis for transthyretin amyloid cardiomyopathy (ATTR-CM). Acoramidis, approved by various regulatory bodies under different brand names, is highlighted as a first-line treatment and a near-complete TTR stabilizer. The presentations aim to further strengthen the drug's clinical profile.
BridgeBio to Present New Acoramidis Data from Open-Label Extension Analyses in ATTR-CM at ESC Congress 2026
BridgeBio Pharma, Inc. announced that new acoramidis data for transthyretin amyloid cardiomyopathy (ATTR-CM) will be presented at the European Society of Cardiology (ESC) Congress 2026. The presentations will highlight acoramidis's clinical profile, including its ability to reduce cardiovascular-related hospitalizations and improve quality of life, reinforcing its role as a first-line treatment. Additionally, BridgeBio's partnership with Yale's Cardiovascular Data Science Lab will feature AI-driven research for earlier detection of ATTR-CM.
BridgeBio Pharma Announces New Acoramidis Data Presentations at ESC Congress 2026 for ATTR-CM
BridgeBio Pharma will present new data on acoramidis, a treatment for transthyretin amyloid cardiomyopathy (ATTR-CM), at the ESC Congress 2026. The presentations will highlight acoramidis's efficacy as a first-line treatment, its ability to reduce cardiovascular-related hospitalizations, and improve patients' quality of life. The company will also showcase AI advancements for early disease detection, developed in partnership with Yale's Cardiovascular Data Science Lab.
BridgeBio Pharma Inc (XTER:2CL) Stock Price & 30 Year Financial Data
This article provides detailed 30-year financial data for BridgeBio Pharma Inc (XTER:2CL), including growth rates for revenue, EPS, EBIT, EBITDA, and free cash flow. It also presents current market capitalization, enterprise value, and various financial ratios, alongside information on how GuruFocus calculates these metrics.
Insider Selling: BridgeBio Pharma (NASDAQ:BBIO) CEO Sells 34,980 Shares of Stock
BridgeBio Pharma CEO Neil Kumar sold 34,980 shares of the company's stock for approximately $2.89 million, reducing his holdings by 12.57%. This sale occurred as BridgeBio reported a quarterly loss that missed analyst estimates, although revenue saw a significant year-over-year increase. Despite the insider selling and a slight stock decline, analysts maintain a "Moderate Buy" rating with an average price target of $100.79.
Neil Kumar Sells 10,000 Shares of BridgeBio Pharma (NASDAQ:BBIO) Stock
BridgeBio Pharma CEO Neil Kumar recently sold 10,000 shares of the company's stock for $840,300, reducing his ownership by 1.94%. This transaction, along with previous sales, was made under a pre-arranged Rule 10b5-1 trading plan. Despite the insider selling and a recent earnings miss, analysts generally maintain a "Moderate Buy" rating for BBIO with a consensus price target of $100.79.
Bridgebio Pharma Insider Sold Shares Worth $3,727,251, According to a Recent SEC Filing
An insider at Bridgebio Pharma (BBIO) recently sold shares valued at $3,727,251, according to a recent SEC filing. The company, a biopharmaceutical firm focused on genetic diseases, had its shares trading at $82.94 USD with a slight daily decrease but significant year-to-date growth. This transaction follows other recent news regarding the company's secondary offering and Q2 2026 earnings report.
Family trust tied to BridgeBio (NASDAQ: BBIO) plans new stock sale
A family trust associated with BridgeBio Pharma, Inc. (BBIO), the Kumar Haldea Family Irrevocable Trust, intends to sell 30,000 shares of common stock valued at approximately $2.49 million. This sale, detailed in a Form 144 SEC filing, follows previous 10b5-1 sales by Neil Kumar and related trusts. The shares originated from a "Conversion Management Incentive Units" acquisition in 2016.
Will BridgeBio’s (BBIO) US$390 Million Raise and Late‑Stage Pipeline Progress Change Its Narrative?
BridgeBio Pharma, Inc. recently completed a US$390 million equity offering and reported Q2 2026 revenues of US$243.68 million with a net loss of US$152.22 million. The company also highlighted new clinical data for Attruby and advanced its rare-disease pipeline with regulatory progress for BBP-418 and encaleret. This fresh capital and pipeline progress are expected to support its genetic medicines portfolio and potentially reshape BridgeBio’s investment narrative, although ongoing net losses and future capital needs remain a key risk.
BridgeBio (NASDAQ: BBIO) CEO has 71K RSUs vest, withholds shares for taxes
BridgeBio Pharma, Inc. CEO Neil Kumar had 71,217 Restricted Stock Units (RSUs) convert into common stock on August 16, 2026. To cover tax obligations from this vesting, 36,237 shares were withheld at $79.86 per share. Following these transactions, Kumar's indirect holdings across various trusts were reported, totaling over 4.8 million shares, while he disclaims beneficial ownership except for any pecuniary interest.
BridgeBio (NASDAQ: BBIO) insider plans $2.8M stock sale
BridgeBio Pharma, Inc. (BBIO) insider Neil Kumar plans to sell 34,980 shares of common stock, valued at approximately $2.8 million, under Rule 144. The filing also details previous Rule 10b5-1 plan sales by Kumar and related trusts over the past three months. This sale represents a small fraction of the 195,487,474 shares outstanding as of August 18, 2026.
